Foresight Diagnostics Announces $58.75 Million Series B Financing Led By Foresite Capital To Commercialize Ultrasensitive Liquid Biopsy Mrd Testing Platform

Apr 27, 2023•over 2 years ago

Amount Raised

$58.8 Million

Round Type

series b

AuroraBiotechnologyHealth CareHealth DiagnosticsTherapeutics

Investors

University Of Colorado Healthcare Innovation FundStanford UniversityAgent CapitalPear VenturesBluebird VenturesCivilization VenturesForesite Capital

Description

Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and The University of Colorado Healthcare Innovation Fund. The proceeds will be used to accelerate the clinical development and commercialization of Foresight Diagnostics' cancer recurrence testing platform, PhasED-SeqTM.

Company Information

Company

Foresight Diagnostics

Location

Aurora, Illinois, United States

About

Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests (with a detection limit below 0.0001%, or one part-per-million). The improved sensitivity of the Foresight's MRD assays can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumors and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on Twitter and LinkedIn.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends